Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

• Unité de recherche: INNOSUISSE
• Numéro de projet: 13071.1 PFLS-LS
• Titre du projet anglais: Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

Description succincte (Allemand)

Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

Description succincte (Anglais)

Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

Résumé des résultats (Abstract) (Allemand)

This R&D/Clinical project aims at evaluating the potential effect of a new therapeutic compound, called MDPK67b, for treatment of hormone refractory prostate cancer in a first in man clinical trial in healthy volunteers. The safety and tolerability of MDPK67b in humans will be established to assess its pharmacokinetic profile (PK) in escalating single and repeated doses, and to collect pharmacodynamic (PD) data. It will be important to confirm its biochemical efficacy profile and design rationally a phase II proof of concept trial in patients. Relevant ex vivo tests for determination of drug PD will be developed and used in the clinical trial.

Résumé des résultats (Abstract) (Anglais)

This R&D/Clinical project aims at evaluating the potential effect of a new therapeutic compound, called MDPK67b, for treatment of hormone refractory prostate cancer in a first in man clinical trial in healthy volunteers. The safety and tolerability of MDPK67b in humans will be established to assess its pharmacokinetic profile (PK) in escalating single and repeated doses, and to collect pharmacodynamic (PD) data. It will be important to confirm its biochemical efficacy profile and design rationally a phase II proof of concept trial in patients. Relevant ex vivo tests for determination of drug PD will be developed and used in the clinical trial.